Secukinumab in moderate to severe hidradenitis suppurativa: Week 16 results of hurley stage II and III from the sunshine and sunrise phase 3 randomized trials

被引：0
|
作者：
Kimball, Alexa B. [1 ,2 ]
Alavi, Afsaneh [3 ,4 ]
Jemec, Gregor B. E. [3 ,5 ]
Zouboulis, Christos C. [3 ,6 ,7 ,8 ,9 ,10 ]
Wozniak, Magdalena B. [11 ]
Uhlmann, Lorenz [12 ]
Llobet-Martinez, Angela [12 ]
Ravichandran, Shoba [13 ]
Marzano, Angelo V. [3 ,14 ,15 ]
Reguiai, Ziad [3 ,16 ]
机构：
[1] Harvard Med Sch, Boston, MA USA
[2] Beth Israel Deaconess Med Ctr, Dermatol, Boston, MA USA
[3] European Hidradenitis Suppurat Fdn eV, Dessau, Germany
[4] Mayo Clin, Dermatol, Rochester, MN USA
[5] Zealand Univ Hosp Roskilde, Dermatol, Roskilde, Denmark
[6] Brandenburg Med Sch Theodor Fontane, Dessau, Germany
[7] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Dermatol, Dessau, Germany
[8] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Venereol, Dessau, Germany
[9] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Allergol, Dessau, Germany
[10] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Immunol, Dessau, Germany
[11] Novartis Ireland Ltd, Dublin, Ireland
[12] Novartis Pharma AG, Basel, Switzerland
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[15] Univ Milan, Dermatol Pathophysiol & Transplantat, Milan, Italy
[16] Polyclin Courlancy Bezannes, Dermatol, Reims, France
来源：
EXPERIMENTAL DERMATOLOGY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [41] Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
    Kokolakis, Georgios
    Warren, Richard B.
    Strober, Bruce
    Blauvelt, Andrew
    Puig, Luis
    Morita, Akimichi
    Gooderham, Melinda
    Koerber, Andreas
    Vanvoorden, Veerle
    Wang, Maggie
    de Cuyper, Dirk
    Madden, Cynthia
    Gomez, Natalie Nunez
    Lebwohl, Mark
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (03) : 330 - 340
  • [42] Patient subgroups; pooled analysis from the phase 3, PIONEER studies of adalimumab treatment in patients with moderate to severe hidradenitis suppurativa
    Jemec, Gregor B. E.
    Gulliver, Wayne P. F.
    Geng, Ziqian
    Iezzi, Annalisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB190 - AB190
  • [43] Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
    Kimball, Alexa B.
    Jemec, Gregor B. E.
    Sayed, Christopher J.
    Kirby, Joslyn S.
    Prens, Errol
    Ingram, John R.
    Garg, Amit
    Gottlieb, Alice B.
    Szepietowski, Jacek C.
    Bechara, Falk G.
    Giamarellos-Bourboulis, Evangelos J.
    Fujita, Hideki
    Rolleri, Robert
    Joshi, Paulatsya
    Dokhe, Pratiksha
    Muller, Edward
    Peterson, Luke
    Madden, Cynthia
    Bari, Muhammad
    Zouboulis, Christos C.
    LANCET, 2024, 403 (10443): : 2504 - 2519
  • [44] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase III, randomized, controlled trial (esteem 1)
    Reich, K.
    Papp, K.
    Leonardi, C.
    Kircik, L.
    Chimenti, S.
    Hu, C.
    Stevens, R.
    Day, R. M.
    Griffiths, C. E.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 22 - 23
  • [45] Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: Pooled results from randomized phase III trials
    Gordon, K
    Pariser, D
    Langley, R
    Caro, I
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P1 - P1
  • [46] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [47] Adalimumab is associated with reduced skin pain in patients with moderate to severe hidradenitis suppurativa (HS): Results from the first 12 weeks of PIONEER II
    Kimball, Alexandra B.
    Pinsky, Brett
    Sundaram, Murali
    Geng, Ziqian
    Okun, Martin
    Bao, Yanjun
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB39 - AB39
  • [48] Time to response in patients with moderate-to-severe hidradenitis suppurativa who were treated with adalimumab: Results from PIONEER I and PIONEER II
    Sobell, Jeffrey
    Brooks, David M.
    Geng, Ziqian
    Teixeira, Henrique D.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB75 - AB75
  • [49] Efficacy and safety of adalimumab treatment in women with moderate to severe hidradenitis suppurativa: Analysis from the placebo-controlled portion of a phase II, randomized, double-blind study
    Gottlieb, Alice B.
    Menter, Alan
    Teixeira, Henrique D.
    Belknap, Kimberly R.
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB49 - AB49
  • [50] Adalimumab improves treatment satisfaction with medication (TS-M) in patients with moderate to severe hidradenitis suppurativa (HS) in a 12-week randomized controlled trial (PIONEER II)
    Jemec, Gregor B. E.
    Sundaram, Murali
    Pinsky, Brett
    Shu, Lei
    Okun, Martin
    Bao, Yanjun
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB39 - AB39
12345